ArticlePloS one2013
Expression of osteopontin in patients with thyroid dysfunction.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Safety of bovine milk osteopontin as a Novel food pursuant to Regulation (EU) 2015/2283.EFSA journal. European Food Safety Authority · 2022Article
- The Most Promising Biomarkers of Allogeneic Kidney Transplant Rejection.Journal of immunology research · 2022Review
- The Potential Role of Osteopontin in the Pathogenesis of Graves' Ophthalmopathy.Investigative ophthalmology & visual science · 2021Article
- Osteopontin Levels in Human Milk Are Related to Maternal Nutrition and Infant Health and Growth.Nutrients · 2021Article
- Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.Disease markers · 2018Review
- Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease.BMC medicine · 2017Review
- Effect of Thyrotropin on Osteopontin, Integrin αInternational journal of molecular sciences · 2016Article
- Thyroid hormone and P-glycoprotein in tumor cells.BioMed research international · 2015Review
- Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes.Molecular metabolism · 2014Review
- The Association Between Inflammatory Biomarkers and Vitamin D Level With the Evolution and Severity of Stroke.Basic and clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid dysfunctions are common endocrine problems. They are often misdiagnosed, misunderstood, and frequently overlooked. These disorders affect almost every aspect of health. Most of them remain undetected because the clinical assessment alone lacks both sensitivity and specificity. As it is not sufficient enough we require the biochemical tests to confirm the diagnosis. As a consequence there is still great interest in new biomarkers that complement existing diagnostic tools. Osteopontin, a glycoprotein that can be detected in plasma, was found to be upregulated in several patients with hyperthyroidism and downregulated in hypothyroid patients so it may represent a new biomarker. 100 patients with thyroid dysfunctions (50 hyperthyroid, 50 hypothyroid) and 100 normal subjects were included in the study. Osteopontin and other clinical parameters for diagnosis of thyroid disorders were measured. Osteopontin is positively correlated with T3 and T4 (r = 0.62 and r = 0.75 respectively) while it is negatively correlated with thyroid stimulating hormone (r = -0.52) showing a significant correlation (p-value <0.001). Our findings suggest that osteopontin might be useful as a novel prognostic biomarker in patients with impaired thyroid function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.